Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Pharmacologic Inhibition of β-Catenin With Pyrvinium Inhibits Murine and Human Models of Wilms Tumor.

Polosukhina D, Love HD, Moses HL, Lee E, Zent R, Clark PE.

Oncol Res. 2017 Nov 2;25(9):1653-1664. doi: 10.3727/096504017X14992942781895. Epub 2017 Jul 10.

2.

Functional KRAS mutations and a potential role for PI3K/AKT activation in Wilms tumors.

Polosukhina D, Love HD, Correa H, Su Z, Dahlman KB, Pao W, Moses HL, Arteaga CL, Lovvorn HN 3rd, Zent R, Clark PE.

Mol Oncol. 2017 Apr;11(4):405-421. doi: 10.1002/1878-0261.12044. Epub 2017 Mar 15.

3.

Genetic variation frequencies in Wilms' tumor: A meta-analysis and systematic review.

Deng C, Dai R, Li X, Liu F.

Cancer Sci. 2016 May;107(5):690-9. doi: 10.1111/cas.12910. Epub 2016 Mar 18. Review.

4.

Deducing the stage of origin of Wilms' tumours from a developmental series of Wt1-mutant mice.

Berry RL, Ozdemir DD, Aronow B, Lindström NO, Dudnakova T, Thornburn A, Perry P, Baldock R, Armit C, Joshi A, Jeanpierre C, Shan J, Vainio S, Baily J, Brownstein D, Davies J, Hastie ND, Hohenstein P.

Dis Model Mech. 2015 Aug 1;8(8):903-17. doi: 10.1242/dmm.018523. Epub 2015 May 14.

5.

Clinical next generation sequencing of pediatric-type malignancies in adult patients identifies novel somatic aberrations.

Silva JG, Corrales-Medina FF, Maher OM, Tannir N, Huh WW, Rytting ME, Subbiah V.

Oncoscience. 2015 Feb 20;2(2):187-92. eCollection 2015.

6.

The IGF signalling pathway in Wilms tumours--a report from the ENCCA Renal Tumours Biology-driven drug development workshop.

Maschietto M, Charlton J, Perotti D, Radice P, Geller JI, Pritchard-Jones K, Weeks M.

Oncotarget. 2014 Sep 30;5(18):8014-26.

7.

Is Wilms tumor a candidate neoplasia for treatment with WNT/β-catenin pathway modulators?--A report from the renal tumors biology-driven drug development workshop.

Perotti D, Hohenstein P, Bongarzone I, Maschietto M, Weeks M, Radice P, Pritchard-Jones K.

Mol Cancer Ther. 2013 Dec;12(12):2619-27. doi: 10.1158/1535-7163.MCT-13-0335. Epub 2013 Nov 20. Review.

8.

Wilms' tumor 1 gene (WT1) is overexpressed and provides an oncogenic function in pediatric nephroblastomas harboring the wild-type WT1.

Sangkhathat S, Kanngurn S, Chaiyapan W, Gridist P, Maneechay W.

Oncol Lett. 2010 Jul;1(4):615-619. Epub 2010 Jul 1.

9.

Clinically relevant subsets identified by gene expression patterns support a revised ontogenic model of Wilms tumor: a Children's Oncology Group Study.

Gadd S, Huff V, Huang CC, Ruteshouser EC, Dome JS, Grundy PE, Breslow N, Jennings L, Green DM, Beckwith JB, Perlman EJ.

Neoplasia. 2012 Aug;14(8):742-56.

10.

WTX R353X mutation in a family with osteopathia striata and cranial sclerosis (OS-CS): case report and literature review of the disease clinical, genetic and radiological features.

Zicari AM, Tarani L, Perotti D, Papetti L, Nicita F, Liberati N, Spalice A, Salvatori G, Guaraldi F, Duse M.

Ital J Pediatr. 2012 Jun 20;38:27. doi: 10.1186/1824-7288-38-27. Review.

11.

Inactivation of X-linked tumor suppressor genes in human cancer.

Liu R, Kain M, Wang L.

Future Oncol. 2012 Apr;8(4):463-81. doi: 10.2217/fon.12.26. Review.

12.

Wilms tumor gene on X chromosome (WTX) inhibits degradation of NRF2 protein through competitive binding to KEAP1 protein.

Camp ND, James RG, Dawson DW, Yan F, Davison JM, Houck SA, Tang X, Zheng N, Major MB, Moon RT.

J Biol Chem. 2012 Feb 24;287(9):6539-50. doi: 10.1074/jbc.M111.316471. Epub 2012 Jan 3.

13.

β-Catenin and K-RAS synergize to form primitive renal epithelial tumors with features of epithelial Wilms' tumors.

Clark PE, Polosukhina D, Love H, Correa H, Coffin C, Perlman EJ, de Caestecker M, Moses HL, Zent R.

Am J Pathol. 2011 Dec;179(6):3045-55. doi: 10.1016/j.ajpath.2011.08.006. Epub 2011 Oct 8.

14.

Structural and functional characterization of the Wnt inhibitor APC membrane recruitment 1 (Amer1).

Tanneberger K, Pfister AS, Kriz V, Bryja V, Schambony A, Behrens J.

J Biol Chem. 2011 Jun 3;286(22):19204-14. doi: 10.1074/jbc.M111.224881. Epub 2011 Apr 15.

15.

Wilms' tumours: about tumour suppressor genes, an oncogene and a chameleon gene.

Huff V.

Nat Rev Cancer. 2011 Feb;11(2):111-21. doi: 10.1038/nrc3002. Epub 2011 Jan 20. Review.

16.

Mutations in the WTX-gene are found in some high-grade microsatellite instable (MSI-H) colorectal cancers.

Scheel SK, Porzner M, Pfeiffer S, Ormanns S, Kirchner T, Jung A.

BMC Cancer. 2010 Aug 9;10:413. doi: 10.1186/1471-2407-10-413.

17.

X-linked tumor suppressors: perplexing inheritance, a unique therapeutic opportunity.

Liu Y, Wang L, Zheng P.

Trends Genet. 2010 Jun;26(6):260-5. doi: 10.1016/j.tig.2010.03.004. Epub 2010 Apr 29.

18.

Loss of heterozygosity at 2q37 in sporadic Wilms' tumor: putative role for miR-562.

Drake KM, Ruteshouser EC, Natrajan R, Harbor P, Wegert J, Gessler M, Pritchard-Jones K, Grundy P, Dome J, Huff V, Jones C, Aldred MA.

Clin Cancer Res. 2009 Oct 1;15(19):5985-92. doi: 10.1158/1078-0432.CCR-09-1065. Epub 2009 Sep 29.

Supplemental Content

Support Center